1. Treating HIV Infection:

2. HIV/AIDS Treatment A Dynamic Field

3. SINGLE Study Phase 3, Open-Label Extension Results, Weeks 96 to 144

4. Dolutegravir Clinical Trials Phase 3 Open-Label Extension Results, Weeks 96 to 144 (cont)

5. Pharmacoenhancers What's New?

6. COBI* vs RTV as a Pharmacoenhancer for TDF/FTC Efficacy Results at 144 Weeks

7. COBI vs RTV as a Pharmacoenhancer for TDF/FTC Safety Results at 144 Weeksa (cont)

8. COBI vs RTV as a Pharmacoenhancer for TDF/FTC Safety Results at 144 Weeks (cont)

9. Low Bone Mineral Density An Age- and ART-Related Comorbidity in People With HIV Infection

10. TAF: A Novel Tenofovir Prodrug Phase 2: DRV/cobi + TAF/FTC vs DRV/cobi + TDF/FTC: Efficacy

11. DRV/cobi + TAF/FTC vs DRV/cobi + TDF/FTC BMD Changes

12. DRV/r + RAL vs TDF/FTC Effect on BMD at 96 Weeks

13. Renal Markers More Favorable for TAF Compared With TDF Renal Function at 48 Weeks

14. Cabotegravir Injectable Long-acting Integrase Strand Transfer Inhibitors Dose-finding Study

15. Abbreviations

16. Abbreviations (cont)

17. References

18. References (cont)

19. References (cont)